NEW YORK (GenomeWeb News) – Orchid Cellmark said today that its first-quarter revenues rose 3.6 percent with US sales up 21 percent but offset by lower revenues in the UK. The firm’s net loss climbed 35.3 percent, which the firm said was primarily due to legal costs.
 
The Princeton, NJ-based DNA testing services firm brought in revenues of $14.5 million for the three-month period ended March 31, compared to revenues of $14 million in the first quarter of 2007.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.